Persistent bone marrow failure with dysplastic features following pentostatin therapy for hairy cell leukaemia

Clin Lab Haematol. 1998 Jun;20(3):195-7. doi: 10.1046/j.1365-2257.1998.00118.x.

Abstract

Myelodysplastic syndromes (MDS) have rarely been reported after treatment with nucleoside analogues, and mainly in patients who have also received alkylating agents. We report a patient who developed MDS (refractory anaemia with ring sideroblasts) after treatment with pentostatin (deoxycoformycin) alone.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Deaminase Inhibitors
  • Aged
  • Anemia, Refractory / chemically induced*
  • Antibiotics, Antineoplastic / adverse effects*
  • Antibiotics, Antineoplastic / therapeutic use
  • Blood Transfusion
  • Bone Marrow / pathology
  • Combined Modality Therapy
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Leukemia, Hairy Cell / complications
  • Leukemia, Hairy Cell / drug therapy*
  • Leukemia, Hairy Cell / therapy
  • Male
  • Neutropenia / chemically induced*
  • Pentostatin / adverse effects*
  • Pentostatin / therapeutic use
  • Remission Induction

Substances

  • Adenosine Deaminase Inhibitors
  • Antibiotics, Antineoplastic
  • Enzyme Inhibitors
  • Pentostatin